2013 ACR/ARHP Annual Meeting

October 25-30, 2013. San Diego, CA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2354

Drug Survival Rates Of Anti-Tumor Necrosis Factor Therapies In Patients With Rheumatoid Arthritis and Ankylosing Spondylitis
Abstract Number: 1558

Drug Trends In Psoriatic Arthritis
Abstract Number: 1580

Drug-Resistant Bloodstream Infections In Systemic Lupus Erythematosus Patients: A Clinical Perspective
Abstract Number: 948

Dual Neutralization Of TNF and IL-17 Provides Greater Efficacy In Collagen Induced Arthritis Through Regulation Of a Gene Transcription Program That Includes CXCL1 and CXCL5
Abstract Number: 212

Dual-Energy Computed Tomography for Monitoring of Urate Deposition in Tophaceous Gout: A Prospective Longitudinal Study Examining Sensitivity to Change
Abstract Number: 107

Duration Of Symptoms Before Diagnosis In Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Abstract Number: 2609

Dutch Translation and Validation Of The University of California, Los Angeles scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument 2.0
Abstract Number: 1835

Dynamic Visualization Of Monocyte Migration In 3D Synovial Micromass Tissue Cultures
Abstract Number: 175

Dynamics Of The Inflammatory Response In Rheumatoid Arthritis Patients Following Traumatic Injury: Insights From In Vivo,In Silico, and Single Nucleotide Polymorphism Studies
Abstract Number: 2641

Earlier Admission To Specialized Care, Intensified Treatment and Improved Outcome In Patients With Autoimmune Connective Tissue Disorders and Vasculitides In Germany 2011 Compared To 1995
Abstract Number: 1733

Early and Sustained Improvement In Pain and Physical Function As Measured By Visual Analog Scale and Short Form-36 Physical Component Summary Score In Rheumatoid Arthritis Patients Treated With Mavrilimumab, An Investigational Anti-GM-CSFR-Alpha Monoclonal Antibody, In a Phase 2a Study
Abstract Number: 1436

Early Changes In a Multi-Biomarker Disease Activity Score After Starting Adalimumab Treatment Predict Change In MRI Inflammation At 6 Months
Abstract Number: 1684

Early Combination Immunosuppression and Serial Non-Invasive Imaging Improves Outcome In Takayasu Arteritis
Abstract Number: 502

Early Introduction Of Biologic Treatment Is An Important Predictor Of Sustained Favorable Outcome Including Clinical Remission In Early Arthritis But Not Of Sustained Favorable Outcome On Structure and Function Only: Results From The Espoir Cohort
Abstract Number: 676

Early Systemic Sclerosis: Marker Autoantibody Positive Patients Have A Faster Pace Of The Disease

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].